Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME1304)

• Drug Name: 5S-HPETE Drug Info
• Synonyms: 5-(S)-hydroperoxyeicosatetraenoic acid; 5S-HpETE

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5280778
  ChEBI ID: CHEBI:15632
  CAS Number: CAS 71774-08-8
  TTD Drug ID: DME1304

Molecule-Related Drug Atlas

Drug(s) Targeting Oxoeicosanoid receptor 1 (OXER1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
5S-HETE	DM3Z6G4	Discovery agent	N.A.	Investigative	[2]
5-oxo-C20:3	DM6FSUW	Discovery agent	N.A.	Investigative	[4]
5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid	DM0K7U5	Discovery agent	N.A.	Investigative	[5]
5-oxo-12-HETE	DMLABR9	Discovery agent	N.A.	Investigative	[6]
5-oxo-15-HETE	DM9ZC7B	Discovery agent	N.A.	Investigative	[7]
Gue1654	DM89KNT	Discovery agent	N.A.	Investigative	[8]
[3H]5-oxo-ETE	DM50WFM	Discovery agent	N.A.	Investigative	[9]
5-oxo-ODE	DM56TVA	Discovery agent	N.A.	Investigative	[10]
5-oxo-20-HETE	DM493GU	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Transient receptor potential cation channel V1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[11]
CNTX-4975	DMB4JPG	Knee osteoarthritis	FA01	Phase 3	[12]
XEN-D0501	DMG7PDY	Overactive bladder	GC50.0	Phase 2	[13]
Resiniferatoxin	DMP62L5	Neuropathic pain	8E43.0	Phase 2	[14]
PAC-14028	DM3816P	Atopic dermatitis	EA80	Phase 2	[15]
GRC-15300	DMWXJSZ	Pain	MG30-MG3Z	Phase 2	[16]
DWP-05195	DMQKU2F	Neuropathic pain	8E43.0	Phase 2	[17]
SB-705498	DMRYHWI	Rhinitis	FA20	Phase 2	[18]
GRC-6211	DMZ0D3V	Asthma	CA23	Phase 1	[19]
ABT-102	DMJFWPR	Chronic pain	MG30	Phase 1	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxoeicosanoid receptor 1 (OXER1)	TT7WBSV	OXER1_HUMAN	Agonist	[2]
Transient receptor potential cation channel V1 (TRPV1)	TTMI6F5	TRPV1_HUMAN	Activator	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2483).
• [2] TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun. 2005 Sep 9;334(4):987-95.
• [3] Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60.
• [4] Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity. J Pharmacol Exp Ther. 2008 May;325(2):698-707.
• [5] 5-Oxo-ETE receptor antagonists. J Med Chem. 2013 May 9;56(9):3725-32.
• [6] Biological inactivation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human platelets. Blood. 1999 Feb 1;93(3):1086-96.
• [7] Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. J Immunol. 1996 Jan 1;156(1):336-42.
• [8] A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer. Nat Chem Biol. 2012 Jul;8(7):631-8.
• [9] Receptors for the 5-oxo class of eicosanoids in neutrophils. J Biol Chem. 1998 Dec 4;273(49):32535-41.
• [10] Human neutrophils convert the sebum-derived polyunsaturated fatty acid Sebaleic acid to a potent granulocyte chemoattractant. J Biol Chem. 2008 Apr 25;283(17):11234-43.
• [11] Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
• [14] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [15] Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
• [16] The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
• [17] TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
• [18] Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
• [19] GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.